Creating advanced cellular devices for cancer detection and treatment
Engineering recombinase circuits for cellular diagnostic devices
['FUNDING_R01'] · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · NIH-11140509
This study is working on creating special cells that can help doctors find cancer more accurately and easily, so patients can get better care.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11140509 on ClinicalTrials.gov |
What this research studies
This research focuses on developing genetically engineered mammalian cells that can serve as highly sensitive diagnostic devices for cancer detection. By utilizing signal amplification genetic circuits, the project aims to enhance the sensitivity and specificity of these cell-based diagnostics beyond traditional methods. The approach involves integrating multiple inputs to improve the accuracy of tumor detection, which could lead to better patient outcomes. The research leverages site-specific recombinases to create circuits that can amplify weak signals, making them more effective in identifying cancer biomarkers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for cancer or those undergoing treatment who could benefit from improved diagnostic methods.
Not a fit: Patients with non-cancerous conditions or those who do not require advanced diagnostic techniques may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and sensitive cancer diagnostics, improving early detection and treatment outcomes for patients.
How similar studies have performed: Other research has shown promise in using genetically engineered cells for diagnostics, indicating that this approach has the potential for significant advancements in cancer detection.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WONG, WILSON — BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
- Study coordinator: WONG, WILSON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy